Intellia Therapeutics Acquires Rewrite Therapeutics

Tome Biosciences Acquires Replace Therapeutics

January 5, 2024

Biotechnology

Tome Biosciences has acquired Replace Therapeutics in a merger valued at $65 million in up-front and near-term milestones and up to $185 million total through a mix of cash and stock. Replace will become a wholly owned subsidiary of Tome, adding its ligase-mediated programmable genomic integration (L-PGI) technology to complement Tome's large-DNA integrase-mediated PGI platform to expand the company's gene‑editing capabilities.

ElevateBio Acquires Life Edit Therapeutics from AgBiome Delta

October 27, 2021

Biotechnology

ElevateBio acquired all of AgBiome Delta, LLC's shares of Life Edit Therapeutics, bringing Life Edit's RNA-guided nuclease and base editor technologies into ElevateBio's cell and gene therapy technology platform. The acquisition expands ElevateBio's genome engineering capabilities to support its in vivo gene therapy pipeline (initial focus on neurologic conditions) and to offer enhanced gene-editing tools and manufacturing access to industry partners.

Inscripta Acquires Infinome Biosciences and Sestina Bio

January 18, 2023

Biotechnology

Inscripta, a genome engineering company based in Pleasanton, California, has acquired synthetic biology firms Infinome Biosciences and Sestina Bio to accelerate its capabilities in sustainable biomanufacturing. The acquisitions integrate Infinome's GenoScaler strain-engineering platform and Sestina's data-driven scale-up strain design to advance Inscripta's commercialization of bio-manufactured products for industrial and consumer markets.

Eclipsebio Acquires Terrain Bio

January 29, 2026

Biotechnology

Eclipse Bioinnovations (Eclipsebio) has acquired Terrain Bio to integrate Terrain's AI/ML RNA design models and R&D-scale mRNA manufacturing analytics into Eclipsebio's sequencing-based validation platforms. The deal creates an end-to-end Design, Make, Test platform intended to accelerate RNA therapeutic development by connecting computational design directly to experimental feedback.

Acuitas Therapeutics Acquires Majority Stake in RNA Technologies & Therapeutics

January 9, 2026

Biotechnology

Acuitas Therapeutics has acquired a majority stake in RNA Technologies & Therapeutics (RNA T&T), deepening a long-standing collaboration to integrate RNA payload design and LNP delivery capabilities. The investment will support RNA T&T's growth—expanding its algorithmic RNA-sequence optimization platform and small-batch GMP production—while both companies continue to operate independently and offer streamlined capabilities to partners.

Kriya Therapeutics Acquires Redpin Therapeutics

November 16, 2022

Biotechnology

Kriya Therapeutics has acquired Redpin Therapeutics, a preclinical New York City–based gene therapy company with a proprietary chemogenetics platform. The deal establishes Kriya's neurology therapeutic-area portfolio by adding Redpin’s lead programs targeting epilepsy and trigeminal neuralgia, and brings chemogenetic capability to Kriya’s gene therapy engine.